# Zhejiang Arthur Pharmaceutical Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/zhejiang-arthur-pharmaceutical-co

- Industry: Pharmaceuticals
- Headquarters: Jiaxing, China
- Website: www.arthurpharma.com
- Latest round: Series B (Jun 3, 2024)
- Investors on record: 12

## About

Established in 2020 and based in Jiaxing, China, Zhejiang Arthur Pharmaceutical Co., Ltd is a drugs' developer that provides generic and innovative drugs. It was recognized as a National High-Tech Enterprise, and has over 2000 square meters of R&D centers located in the USA and Jiaxing. The company has about 100 employees and more than 50% of them have master's degree. The core research team mostly graduated from East China University of Science and Technology, China Pharmaceutical University and Shenyang Pharmaceutical University. In June 2024, Zhejiang Arthur Pharmaceutical closed series B funding.

Arthur Pharmaceutical mainly provides generic and innovative drugs. Its products include oral solid, sterile and semi-solid. Sterile includes lyophilization, drops, liquid self-emulsifying formulations, nanoparticle suspension and liposomes. The products can be used in the treatment of cardiovascular diseases, gastrointestinal disorders, diabetes, central nervous system disorders, as well as for anti-infective and anti-tumor applications. Arthur has more than 60 sets of precision testing instruments and more than 50 sets of preparation synthesis small test and pilot equipment. The company also offers CRO, CMO and CDMO services.

The company generates revenue by offering CRO, CMO and CDMO services and pharmaceuticals such as tablets, capsules, injectables, semi-solid.

The company will expand its strategic presence in the pharmaceutical market as well as international markets.

## Funding rounds

- Series B, Jun 3, 2024 — Addor Capital, Jiuzhi Capital, CMBC Capital Holdings, Ruiying Capital, Zhejiang Age Construction, Win-Win, Ningyang Jingkai Investment, Three Nine Two Seven
- Series A, Jan 31, 2023 — Jiuzhi Capital, CXETDZ
- Series A, Apr 7, 2022 — Addor Capital, Zhejiang Changxing Financial Holding Group, Ruiying Capital, Jiaxing Science and Technology City Industrial Investment Fund Co., Ltd, Yida Capital

## Investors

- Addor Capital (https://capitalatlas.ai/funds/addor-capital) — Series A, Series B
- Zhejiang Changxing Financial Holding Group — Series A
- Ruiying Capital (https://capitalatlas.ai/funds/ruiying-capital) — Series A, Series B
- Jiaxing Science and Technology City Industrial Investment Fund Co., Ltd — Series A
- Yida Capital — Series A
- Jiuzhi Capital (https://capitalatlas.ai/funds/jiuzhi-capital) — Series A, Series B
- CXETDZ — Series A
- CMBC Capital Holdings — Series B
- Zhejiang Age Construction — Series B
- Win-Win — Series B
- Ningyang Jingkai Investment — Series B
- Three Nine Two Seven — Series B